Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

(2018) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Hyperactivation of MAPK Signaling is Deleterious to RAS/RAF Mutant Melanoma

(2018) Grace P Leung et al.   MOLECULAR CANCER RESEARCH

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

(2017) Xiangjun Kong et al.   NATURE

A Braf kinase-inactive mutant induces lung adenocarcinoma

(2017) Patricia Nieto et al.   NATURE

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

(2017) Zhan Yao et al.   NATURE

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

(2017) Collin M Blakely et al.   NATURE GENETICS

Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling

(2017) Andrew M. Kidger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drugging RAS: Know the enemy

(2017) Bjoern Papke et al.   SCIENCE

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma

(2017) Aayoung Hong et al.   Cancer Discovery

Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma

(2017) Stephanie Wittig-Blaich et al.   Oncotarget

Negative feedback regulation of the ERK1/2 MAPK pathway

(2016) David Lake et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma

(2016) C Ambrogio et al.   ONCOGENE

Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics

(2016) Sergio Anastasi et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)

(2016) Andrew M. Kidger et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia

(2015) Seyedmehdi Shojaee et al.   CANCER CELL

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

(2015) Gatien Moriceau et al.   CANCER CELL

Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer

(2015) Lukas E. Dow et al.   CELL

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

(2015) J. Downward   CLINICAL CANCER RESEARCH

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

(2015) J. C. Hunter et al.   MOLECULAR CANCER RESEARCH

Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis

(2015) Zhen Zhao et al.   NATURE GENETICS

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF

(2015) J Cisowski et al.   ONCOGENE

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma

(2015) T. K. Maity et al.   Cancer Discovery

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

(2015) Arun M Unni et al.   eLife

In Vivo Structure-Activity Relationship Studies Support Allosteric Targeting of a Dual Specificity Phosphatase

(2014) Vasiliy N. Korotchenko et al.   CHEMBIOCHEM

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics

(2014) Apirat Chaikuad et al.   Nature Chemical Biology

Improved vectors and genome-wide libraries for CRISPR screening

(2014) Neville E Sanjana et al.   NATURE METHODS

A pan-cancer proteomic perspective on The Cancer Genome Atlas

(2014) Rehan Akbani et al.   Nature Communications

Lessons from the Cancer Genome

(2013) Levi A. Garraway et al.   CELL

Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence

(2013) Jimin Shin et al.   CELLULAR SIGNALLING

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

ERK Pathway Inhibitors: How Low Should We Go?

(2013) M. H. Nissan et al.   Cancer Discovery

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

(2012) W. W. Lockwood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Feedback regulation of EGFR signalling: decision making by early and delayed loops

(2011) Roi Avraham et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo

(2011) Kristen L. Meerbrey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

(2010) Zhenfeng Zhang et al.   CARCINOGENESIS

Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages

(2009) Gabriela Molina et al.   Nature Chemical Biology

Dual-specificity MAP kinase phosphatases (MKPs) and cancer

(2008) Stephen M. Keyse   CANCER AND METASTASIS REVIEWS

Active Ras Triggers Death in Glioblastoma Cells through Hyperstimulation of Macropinocytosis

(2008) J. H. Overmeyer et al.   MOLECULAR CANCER RESEARCH

Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced byMycand mutantKras

(2008) Katrina Podsypanina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA